Format

Send to

Choose Destination
Cytokine Growth Factor Rev. 2017 Aug;36:5-15. doi: 10.1016/j.cytogfr.2017.06.011. Epub 2017 Jun 28.

Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors.

Author information

1
Department of Pulmonary Medicine, Erasmus Medical Center Rotterdam, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands; Erasmus MC Cancer Institute, Erasmus Medical Center Rotterdam, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.
2
Erasmus MC Cancer Institute, Erasmus Medical Center Rotterdam, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands; Department of Surgery, Erasmus Medical Center Rotterdam, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.
3
Department of Surgery, Erasmus Medical Center Rotterdam, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.
4
Department of Clinical Oncology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
5
Department of Pulmonary Medicine, Erasmus Medical Center Rotterdam, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands; Erasmus MC Cancer Institute, Erasmus Medical Center Rotterdam, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. Electronic address: j.aerts@erasmusmc.nl.

Abstract

With the widespread application of immune checkpoint blocking antibodies (ICBs) for the treatment of advanced cancer, immunotherapy has proven to be capable of yielding unparalleled clinical results. However, despite the initial success of ICB-treatment, still a minority of patients experience durable responses to ICB therapy. A plethora of mechanisms underlie ICB resistance ranging from low immunogenicity, inadequate generation or recruitment of tumor-specific T cells or local suppression by stromal cells to acquired genetic alterations leading to immune escape. Increasing the response rates to ICBs requires insight into the mechanisms underlying resistance and the subsequent design of rational therapeutic combinations on a per patient basis. In this review, we aim to establish order into the mechanisms governing primary and secondary ICB resistance, offer therapeutic options to circumvent different modes of resistance and plea for a personalized medicine approach to maximize immunotherapeutic benefit for all cancer patients.

KEYWORDS:

Immune-checkpoint blockade; Immunotherapy; Personalized medicine; Tumor immunology; Tumor microenvironment

PMID:
28693973
DOI:
10.1016/j.cytogfr.2017.06.011
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center